Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04399980
Other study ID # IND 149324
Secondary ID IRB 20-523
Status Completed
Phase Phase 2
First received
Last updated
Start date May 20, 2020
Est. completion date April 23, 2021

Study information

Verified date May 2021
Source The Cleveland Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this prospective, Phase 2, multicenter, blinded, randomized placebo controlled study is to demonstrate that early treatment with mavrilimumab prevents progression of respiratory failure in patients with severe COVID-19 pneumonia and clinical and biological features of hyper-inflammation.


Description:

This prospective, Phase 2, multi-center, blinded randomized placebo-controlled study is designed to demonstrate that early treatment with mavrilimumab prevents progression of respiratory failure in patients with severe Covid-19 pneumonia and clinical and biological features of hyper-inflammation. The study population includes patients who have severe pneumonia, defined as hospitalization due to Covid-19 with abnormal chest imaging and SpO2 <92% on room air or requirement for supplemental oxygen. Enrollment: The study will be performed in approximately 4 months total, starting from the first patient enrolled with enrollment expected to complete within 2 months. Follow-up period: The follow-up period is 60 days for each patient enrolled. A total of 60 patients will be randomized using a 1:1 allocation ratio: 30 subjects will receive mavrilimumab, and 30 subjects will receive placebo infusion. The investigator, clinical team, and subject will be blinded to treatment assignment. Participants will be identified by regular review of hospitalized COVID19 patients to evaluate for inclusion and exclusion criteria. Participants will then be approached in the standard manner by study investigator and coordinator/research nurse. Research interventions will take place in the hospital in accordance with privacy standards. The study team is informed on all study procedures and requirements with daily meetings and the opportunity to continuously update through secure channels. In this multicenter consortium, each participating site will have their own IND for patients enrolled at their site. Data collection will occur at each of the 4 academic centers, and data analysis and randomization scheme will be performed by one site, Cleveland Clinic C5 Research.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date April 23, 2021
Est. primary completion date April 23, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria (must meet all): 1. Written informed consent must be obtained before any assessment is performed 2. Documented COVID19 pneumonia defined as positive SARS-CoV2 test AND abnormalities/ infiltrates on chest x-ray or computed tomography AND active fever or documented fever within 24-48 hours or ongoing anti-pyretic use to suppress fever 3. Hypoxia (Room air SpO2 <92% or requirement for supplemental oxygen) 4. Increased serum inflammatory marker (CRP > 5 mg/dL) 5. Severity of disease warrants inpatient hospitalization Exclusion Criteria: 1. Onset of COVID-19 symptoms >14 days 2. Age < 18 years-old 3. Hospitalized >7 days 4. Mechanically ventilated 5. Serious concomitant illness which in the opinion of the investigator precludes the patient from enrolling in the trial, including (but not limited to): - History of immunodeficiency (congenital or acquired) - Neutropenia (absolute neutrophil count <1,500/mm3) - History of solid-organ or bone marrow transplant - History of current systemic autoimmune or autoinflammatory disease(s) requiring systemic immune-modulating drugs - History of myeloproliferative disorder or active malignancy receiving cytotoxic chemotherapy - Pre-existing severe pulmonary disease (i.e. steroid dependent asthma, COPD on home oxygen, or other restrictive/obstructive lung disease requiring home oxygen) - Pre-existing severe left ventricular systolic dysfunction (i.e. LVEF <35%) - Known or suspected active tuberculosis (TB), latent TB, or history of incompletely treated TB or at high risk for latent TB (from exposure or prior incarceration) - History of active or latent viral hepatitis (i.e. Hepatitis B or C) - Concomitant uncontrolled systemic bacterial or fungal infection - Concomitant viral infection other than COVID-19 (e.g. Influenza, other respiratory viruses) - History of chronic liver disease with portal hypertension - History of end-stage renal disease on chronic renal replacement therapy 6. Recent treatment with cell-depleting biological therapies (e.g., anti-CD20) within 12 months, cell-depleting biological therapies (such as anti-tumor necrosis factor [TNF], anakinra, anti-Interleukin [IL]-6 receptor [e.g. tocilizumab], or abatacept) within 8 weeks (or 5 half-lives, whichever is longer), treatment with alkylating agents within 12 weeks, treatment with cyclosporine A, azathioprine, cyclophosphamide, or mycophenolate mofetil (MMF) within 4 weeks 7. Recent treatment with intramuscular live (attenuated) vaccine within 4 weeks 8. Chronic or recent corticosteroid use > 10 mg/day 9. Pregnant. Breast-feeding women are eligible with the decision to continue or discontinue breast-feeding during therapy taking into account the risk of infant exposure, the benefits of breast-feeding to the infant, and benefits of treatment to the mother 10. Enrolled in another investigational study using immunosuppressive therapy 11. Known hypersensitivity to mavrilimumab or any of its excipients 12. In the opinion of the investigator, unable to comply with the requirements to participate in the study 13. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing of investigational drug. Such methods include: - Total abstinence (when this is in line with the preferred and usual lifestyle of the subject). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception - Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or bilateral tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment - Male sterilization (at least 6 months prior to screening). For female subjects on the study, the vasectomized male partner should be the sole partner for that subject - Use of oral, (estrogen and progesterone), injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception

Study Design


Intervention

Drug:
Mavrilimumab
Treatment infusion
Placebos
Placebo infusion

Locations

Country Name City State
United States Cleveland Clinic Health System Cleveland Ohio
United States Cleveland Clinic Florida Weston Florida

Sponsors (2)

Lead Sponsor Collaborator
The Cleveland Clinic Kiniksa Pharmaceuticals, Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Subjects Alive and Off of Oxygen at Day 14 Number and percentage of subjects alive and off of oxygen at day 14 Day 14
Secondary Number of Subjects Alive and Without Respiratory Failure at Day 28 Number and percentage of subjects that are alive and without respiratory failure at Day 28 Day 28
Secondary Mortality at Day 28 Number and percentage of patients that expired by Day 28 Day 28
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04244474 - Effect of Vitamin D Supplementation on Improvement of Pneumonic Children Phase 1/Phase 2
Completed NCT05815264 - Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and Above Phase 1
Recruiting NCT04589936 - Prone Position to Improve Oxygenation in COVID-19 Patients Outside Critical Care N/A
Completed NCT02905383 - The Effect of Exercise on Physical Function and Health in Older People After Discharge From Hospital N/A
Terminated NCT03944551 - Bubble Continuous Positive Airway Pressure for Children With Severe Pneumonia in Mali, Africa N/A
Completed NCT06210737 - A Study to Evaluate Persistence of Immunity of PCV13 in Healthy Population Aged 2 Months,7 Months-5 Years Phase 4
Terminated NCT04660084 - Impact of Molecular Testing on Improved Diagnosis, Treatment and Management of CAP N/A
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Withdrawn NCT05702788 - Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19) Phase 2
Not yet recruiting NCT04171674 - Pharmacokinetics of High-dose Ceftobiprole in Community-acquired Pneumonia Under Mechanical Ventilation. N/A
Active, not recruiting NCT03140163 - Screening for Pneumonia: A Comparison of Ultra Low Dose Chest CT [ULD-CT] and Conventional Chest Radiography [CXR] N/A
Completed NCT02864420 - Hospitalization at Home: The Acute Care Home Hospital Program for Adults N/A
Completed NCT02638649 - Prehospital Use of Ultrasound in Undifferentiated Shortness of Breath
Recruiting NCT02515565 - Physiotherapy in Patients Hospitalized Due to Pneumonia. N/A
Completed NCT02105298 - Effect of Volume and Type of Fluid on Postoperative Incidence of Respiratory Complications and Outcome (CRC-Study) N/A
Completed NCT01446926 - Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants Phase 1
Completed NCT01416519 - Physiotherapy Technique Decreases Respiratory Complications After Cardiac Operation N/A
Completed NCT01399723 - Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia Phase 3
Terminated NCT02358642 - Drug to Prevent Pneumonia in the Tube Fed Phase 4
Completed NCT01416506 - Community-Acquired Pneumonia (CAP) Surveillance N/A